{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:40:20Z","timestamp":1787946020376,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013955","name":"Astellas Pharma, Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00548-8","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:59:07Z","timestamp":1778320747000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5354-8279","authenticated-orcid":false,"given":"Dianne","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim J. M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"van der Doelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M. A.","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addy C. M.","family":"van de Luijtgaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reindert J. A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter L.","family":"Vervenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir I.","family":"Weijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F. A.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malou C. P.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"548_CR1","unstructured":"Mottet (Chair) NPCV-c, van den Bergh RCN, Briers E, Expert Patient Advocate (European Prostate Cancer Coalition\/Europa UOMO), Eberli D, De Meerleer G, De Santis M, Gillessen S, Grummet J, Henry AM, van der Kwast TH,  van Leenders GJLH, Mason MD, O\u2019Hanlon S, van Oort IM, Oprea-Lager DE, Ploussard G,  Rouvi\u00e8re O, Schoots IG, Stranne J, Tilki D,  Wiegel T. EAU - EANM - ESTRO - ESUR-ISUP-SIOG Guidelines on Prostate Cancer. 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment. Accessed 23 Feb 2024."},{"key":"548_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00029","author":"W Abida","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00029.","journal-title":"JCO Precis Oncol"},{"key":"548_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601. https:\/\/doi.org\/10.3389\/fcell.2020.564601.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"548_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05188-7","volume":"42","author":"M Hommerding","year":"2024","unstructured":"Hommerding M, Hommerding O, Bernhardt M, Kreft T, Sanders C, Tischler V, et al. Real-world data on the prevalence of BRCA1\/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer. World J Urol. 2024;42(1):491. https:\/\/doi.org\/10.1007\/s00345-024-05188-7.","journal-title":"World J Urol"},{"issue":"5","key":"548_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001.","journal-title":"Cell"},{"key":"548_CR6","unstructured":"European Commission-Union Register of medicinal products for human use\u2014Lynparza. 2020. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h959.htm. Accessed 19 Mar 2024."},{"key":"548_CR7","unstructured":"FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. (2020). Accessed 19-03-2024."},{"issue":"22","key":"548_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"issue":"24","key":"548_CR9","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2022485.","journal-title":"N Engl J Med"},{"issue":"26","key":"548_CR10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1911206.","journal-title":"N Engl J Med"},{"issue":"12","key":"548_CR11","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20(12):1730\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30688-6.","journal-title":"Lancet Oncol"},{"issue":"9","key":"548_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"issue":"9","key":"548_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043. https:\/\/doi.org\/10.1056\/EVIDoa2200043.","journal-title":"NEJM Evid"},{"key":"548_CR14","unstructured":"(FDA) USFDA: FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer. 2023. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration. Accessed 19 Mar 2024."},{"issue":"1","key":"548_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00461","volume":"6","author":"MJ Price","year":"2022","unstructured":"Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B. Homologous recombination repair gene variants and outcomes among patients with prostate cancer treated with Poly (ADP-ribose) Polymerase inhibitors. JCO Precis Oncol. 2022;6(1):e2100461. https:\/\/doi.org\/10.1200\/PO.21.00461.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"548_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.prnil.2022.04.005","volume":"10","author":"J Pan","year":"2022","unstructured":"Pan J, Ye D, Zhu Y. Olaparib outcomes in metastatic castration-resistant prostate cancer: first real-world experience in safety and efficacy from the Chinese mainland. Prostate Int. 2022;10(3):142\u20137. https:\/\/doi.org\/10.1016\/j.prnil.2022.04.005.","journal-title":"Prostate Int"},{"issue":"5","key":"548_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01648-5","volume":"39","author":"B Dong","year":"2022","unstructured":"Dong B, Yang B, Chen W, Du X, Fan L, Yao X, et al. Olaparib for Chinese metastatic castration-resistant prostate cancer: a real-world study of efficacy and gene predictive analysis. Med Oncol. 2022;39(5):96. https:\/\/doi.org\/10.1007\/s12032-022-01648-5.","journal-title":"Med Oncol"},{"key":"548_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153808","author":"D Bosch","year":"2023","unstructured":"Bosch D, Kuppen MCP, Tascilar M, Smilde TJ, Mulders PFA, Uyl-de Groot CA, et al. Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry driven by artificial intelligence. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153808.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"548_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"5","key":"548_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. J Nucl Med. 2020;61(5):678\u201382. https:\/\/doi.org\/10.2967\/jnumed.119.233817.","journal-title":"J Nucl Med"},{"issue":"8","key":"548_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2217\/fon-2021-1113","volume":"18","author":"A Leith","year":"2022","unstructured":"Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. Future Oncol. 2022;18(8):937\u201351. https:\/\/doi.org\/10.2217\/fon-2021-1113.","journal-title":"Future Oncol"},{"issue":"5","key":"548_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479\u2013505. https:\/\/doi.org\/10.6004\/jnccn.2019.0023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"548_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"key":"548_CR24","unstructured":"(FMS) FMS: Prostaatcarcinoom - Richtlijn. https:\/\/richtlijnendatabase.nl\/richtlijn\/prostaatcarcinoom\/prostaatcarcinoom_-_korte_beschrijving.html (2016). Accessed 9 Sep 2025."},{"key":"548_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/CEOR.S468680","volume":"16","author":"MA Bilen","year":"2024","unstructured":"Bilen MA, Khilfeh I, Rossi C, Muser E, Morrison L, Hilts A, et al. Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. Clinicoecon Outcomes Res. 2024;16:657\u201374. https:\/\/doi.org\/10.2147\/CEOR.S468680.","journal-title":"Clinicoecon Outcomes Res."},{"key":"548_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.02.005","author":"J Xie","year":"2024","unstructured":"Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, et al. Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.02.005.","journal-title":"Eur Urol Oncol"},{"key":"548_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.006","volume":"43","author":"D George","year":"2025","unstructured":"George D, Kariburyo-Yay F, Aggarwal H, Tepsick J, Yu R, Li W, et al. Real-world treatment and clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with olaparib in the United States. Urol Oncol. 2025;43:2. https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.006.","journal-title":"Urol Oncol"},{"issue":"5","key":"548_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024;42(5):571\u201383. https:\/\/doi.org\/10.1200\/JCO.23.00339.","journal-title":"J Clin Oncol"},{"issue":"8","key":"548_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2214676.","journal-title":"N Engl J Med"},{"key":"548_CR30","doi-asserted-by":"crossref","unstructured":"Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, \u00d6zg\u00fcro\u011flu M, et al. Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. In: 2025 ASCO Annual Meeting II. Chicago, IL, USA.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00548-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:51Z","timestamp":1782098391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00548-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00548-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"10 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D. Bosch received speaker honoraria from MSD. A.M. Bergman received research grants and honoraria from Astellas, Sanofi, Bayer, and Janssen. M.J. van der Doelen received research grants from Bayer and Janssen and received speaker fees from Astellas. A.J.M. van den Eertwegh received study grants from Bristol-Myers Squibb and Idera and travel fees from Ipsen, and is a member of the advisory boards of Bristol-Myers Squibb, MSD Oncology, Ipsen, Pierre Fabre, and Janssen. A.C.M. van de Luijtgaarden received honoraria from Astellas, Bayer, Eisai, Ipsen, Janssen, MSD\/AstraZeneca, AAA Novartis, and Pfizer, and is a member of the advisory board for the Dutch Prostate Cancer Foundation. N. Mehra reports grants from Janssen-Cilag, Astellas Pharma, AstraZeneca, Bristol Myers Squibb Foundation, and MSD Oncology and personal and institutional fees for consulting or advisory role from Janssen-Cilag, Astellas Pharma, AstraZeneca, MSD Oncology, Bayer, and Pfizer. R.J.A. van Moorselaar received speaker fees from or is a member of the advisory boards of Astellas, AstraZeneca, Bayer, BMS, Curium, Janssen and Pantarhei Bioscience. W.L. Vervenne received honoraria from Servier Nederland Farma. P.F.A. Mulders received research funds from Astellas, AstraZeneca, Telix, and Byondis. M.C.P. Kuppen received research grants from AAA Novartis, Astellas, Bayer, and MSD\/AstraZeneca. I.M. van Oort is a member of the advisory boards for MSD\/AstraZeneca, Pfizer, Astellas, and Bayer; received a research grant from AAA Novartis; and received research grants and personal fees from Astellas, Bayer, Janssen Pharmaceuticals, MSD\/AstraZeneca, and Pfizer. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Research Ethics Committee Oost-Nederland (CMO 2020-6573) and all participating institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from living patients by the treating physician, except for those lost to follow-up.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The custom code (SPSS syntaxes) and datasets generated and\/or analyzed during the current study are not publicly available due to license agreements between the CAPRI foundation, participating hospitals, and sponsoring parties, but are available from the corresponding author on reasonable request and with permission of the CAPRI foundation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Code, Data, and Material"}},{"value":"DB and KJMV performed the acquisition and (statistical) analysis of data. DB interpretated the data and drafted the manuscript. MCPK and IMO obtained funding, performed administrative support, and provided supervision. All authors contributed to the conception and design and critical revision of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}